MYC and non-Hodgkin lymphoma: In our in vitro studies we observed potent anti-tumor activity of selinexor in MYC and BCL2/6 “double-hit” DLBCL, while the clinical responses were observed across all subtypes of NHL independent of genetic abnormalities.